AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04106180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Patients will receive GM-CSF 125μg/m2 daily for 14 consecutive days after completing SBRT treatment.
Study NCT04106180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Patients will receive Sintilimab 200 mg every 3 weeks up to 2 years after completing SBRT treatment.
Study NCT04106180 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients will receive SBRT for one previously unirradiated primary or metastatic lesion (size: 1-5cm). 24 Gy in 3 fractions (8Gy/Fx) administered once-daily for 3 consecutive days.
Study NCT03633513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LBT-3627
Description: Immunomodulatory agent
Study NCT02854631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Selonsertib placebo tablet administered orally once daily
Study NCT04051008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online - use of online grocery shopping platform
Description: The Online intervention will utilize online grocery shopping (shopping at a local grocery store via online platform).
Study NCT03257410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elisio-17H dialyzer
Description: Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
Study NCT03907306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound healing
Description: The measurement of a wound area is committed on the 2nd, 8th, 14th, 21nd and 30th day after operation. By means of the mathematical formulas the wound healing speed will be defined. The wound process will be researched with the help of cytological method. The wound prints will be taken on the 2nd, 8th, 14th, 21nd and 30th day after operation. Microbiological research of a wound will be held on the 2nd, 8th, 14th, 21nd and 30th day after operation (in study groups before and after the usage of CAP, in control groups once). The pain assessment will be measured by a visual analogue scale on the 2nd, 3rd,4th, 5th, 6th, 7th, 8th, 14th, 21nd and 30th day after operation. The life quality will be researched by means of Health Status Survey on the 8th and 30th day before operation.
Study NCT03907306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound healing
Description: The measurement of a wound area is committed on the 2nd, 8th, 14th, 21nd and 30th day after operation. By means of the mathematical formulas the wound healing speed will be defined. The wound process will be researched with the help of cytological method. The wound prints will be taken on the 2nd, 8th, 14th, 21nd and 30th day after operation. Microbiological research of a wound will be held on the 2nd, 8th, 14th, 21nd and 30th day after operation (in study groups before and after the usage of CAP, in control groups once). The pain assessment will be measured by a visual analogue scale on the 2nd, 3rd,4th, 5th, 6th, 7th, 8th, 14th, 21nd and 30th day after operation. The life quality will be researched by means of Health Status Survey on the 8th and 30th day before operation.
Study NCT02624141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Beta
Description: Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
Study NCT01953692 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT03633513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunological profiling
Description: Comprehensive profiling of inflammatory and anti-inflammatory markers (incl. cellular, molecular) including cellular functional assays
Study NCT02947334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bococizumab
Description: Bococizumab PFS
Study NCT02947334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01086449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster Vaccine GSK 1437173A
Description: Investigational vaccine (GSK 1437173A) administered intramuscularly.
Study NCT02946151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UNEEG implantable EEG electrode and data storage device
Description: The implantable EEG electrode will be implanted subcutaneously in the relevant temporal region by a certified neurosurgeon. The EEGgraphical data recorded will be transmitted transcutaneously to the data storage device via an inductive link, providing continuous data on brain activity.
Study NCT05639829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Restriction of calorie intake to an 8-hour window, with water only fasting in the remaining 16 hours of the 24-hour period
Study NCT02611518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 14.
Study NCT01953692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 20 mg
Description: oral capsule
Study NCT01953692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg
Description: oral capsule
Study NCT00799552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10045
Description: RX-10045 eye drop
Study NCT00799552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drop
Study NCT02400931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mask ventilation
Description: In mask ventilation group, rocuronium of 0.6 mg/kg will be administered after the loss of consciousness. Mask ventilation wil be performed until there is no response on the train-of-four stimulus. No mask ventilation - In no mask ventilation group, rocuronium of 1.2 mg/kg will be administered after the loss of consciousness. Tracheal intubation will be performed after confirmation of no response on the train-of-four stimulus. The mask ventilation will not be performed before the tracheal intubation.
Study NCT02400931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no mask ventilation
Study NCT02400931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Study NCT02400931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Study NCT01370343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532 alone
Description: a single dose of 150 mg PF-04991532, fasted
Study NCT01370343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532 + cyclosporine
Description: a single dose of 150 mg PF-04991532 + a single dose of 600 mg cyclosporine, fasted
Study NCT02329639 — intervention group
Intervention type: GENETIC
Intervention: genetic interaction analysis
Description: VEGFR-2 rs11133360/IL-8 rs4073 genetic interaction analysis
Study NCT01019213 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Septal pacing
Description: Septal lead activated
Study NCT01019213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: His lead activated
Description: His lead will be activated 80 ms before septal lead
Study NCT03589625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solar Suitcase
Description: The intervention is a Solar Suitcase. The Solar Suitcase comes with: 2 LED lights, 1 battery, 1 aluminum glass 100 watt solar panel, 2 rechargeable LED headlamps, 1 universal cell phone charger, 1 USB adapter, 1 fetal Doppler, 1 AA/AAA battery charger and expansion box (provides 2 additional lights).~Installers will teach health workers how to use and maintain the Solar Suitcase on the day of installation. Within one week following installation, the contractor will contact the facility over the phone and/or in-person to check if there are any problems with the Suitcase. Additional checks will be made to ensure the solar suitcase is functioning and being used properly.
Study NCT02059616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: Daily oral administration for 8 weeks
Study NCT02059616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg
Description: Daily oral administration for 8 weeks
Study NCT02059616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil 8mg
Description: Daily oral administration for 8 weeks
Study NCT02059616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16mg
Description: Daily oral administration for 8 weeks
Study NCT02076568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education - Diabetes and Partnership
Description: Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Partnership was created. The module covers specific and detailed aspects of the topic partnership such as dealing with hypoglycemia, late complications, and talking about diabetes in a relationship. With this module, a more comprehensive education of patients with specific interest in these topics is possible.
Study NCT02476435 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS
Description: Strong electromagnetic fields (\~2Tesla) generated briefly but repetitively (1Hz) applied for 30mins, in five sessions per week for 3 weeks
Study NCT02476435 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo rTMS
Description: Placebo electromagnetic fields generated briefly but repetitively applied for 30mins, in five sessions per week for 3 weeks
Study NCT02920710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection
Description: * Initial treatment with 80 units daily for ten days (induction phase)~* Maintenance treatment with 80 units twice weekly (maintenance phase)
Study NCT01643499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT01643499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT01643499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01643499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01643499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03117582 — intervention group
Intervention type: OTHER
Intervention: Stool specimen
Description: The following stool specimen will be collected for this study:~1. 4, 3mL stool specimen from patient~2. 1, 25mL stool aliquot from donor
Study NCT02611518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911
Description: JNJ-54861911 will be administered at a dose of 25 mg once daily from Day 8 to Day 17 (in panel 1), Day 8 to 16 (in panel 2).
Study NCT02876016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional MRI
Description: locate the cerebral bases in functional imaging
Study NCT00824642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Applied 45 minutes prior to exercise
Study NCT00824642 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo TENS applied prior to exercise
Study NCT03329482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PULSE ULTRASOUND
Description: For group A, The PUS group received pulse mode of ultrasound (sonoplus 490s), with frequency of 1MHZ and intensity of 1.5w/cm according to Ebadi et al 10). Grey's formula was used to estimate the duration of ultrasound (US) for each patient 21). The average local exposure time was one minute and the effective radiating area of the transducer head was 5 cm2. For a patient with an area of low back pain of 40 cm2, the required total treatment time was: 1 min × (40 cm2/5 cm2) = 8 minutes. US was applied using slow circular movements, with the transducer head placed over the painful paravertebral low back region and Lofnac gel used as coupling medium.
Study NCT03329482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KNEADING MASSAGE
Description: Kneading massage was done with the two hands maintaining a slow circular compression of soft tissues against underlying bone. Pressure was applied as the hands moved proximally, continuously maintaining a contact with the skin, according to Goat22). Lofnac gel was used as a coupling medium for the massage. This was done for an approximately ten and 12 minutes.
Study NCT00909649 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fibrin glue in breast surgery
Description: fibrin glue 8 ml in the bed after modified radical mastectomy in fibrin treated group
Study NCT00291954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-AS02V
Description: HB-AS02V (20µg HBsAg) will be administered at Month 0 and 1
Study NCT00291954 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBVAXPRO vaccine
Description: HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0 and 1
Study NCT03762772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF/EVG Vaginal Insert
Description: 1 combination vaginal insert (20mg TAF/16mg EVG)
Study NCT02582424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD-L0101
Description: 92% EPA+6 mg ATX+50 mg TCT GG BID
Study NCT02582424 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01951807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Study NCT03358446 — intervention group
Intervention type: OTHER
Intervention: A group
Description: The optimal range of leg abduction was defined as the range without overlap in A group and the range presenting that the overlap was less-than half of the diameter of femoral vein in S group.~A1 angle defined the point that the femoral vein and artery started non-overlapping interval when increasing the angle of the leg in the A group and the A2 angle is defined the point that the femoral vein and artery ended non-overlapping interval.
Study NCT03358446 — intervention group
Intervention type: OTHER
Intervention: S group
Description: B1 is the angle at which the overlap starts at the half of the femoral vein radius when increasing the angle of the leg in the S group, B2 is the angle at which overlap starts at half or more of the femoral vein radius again. In the range of B1 and B2 angles, they are overlapped by half or less of the femoral vein radius.
Study NCT02095717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Study NCT02095717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02095717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Study NCT02095717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Taxotere
Study NCT03190850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The device in which the breathing exercises will be performed will be adjusted with progressive loading aiming to improve muscular strength
Study NCT03190850 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The device in which the breathing exercises will be performed will not be adjusted with progressive loading.
Study NCT00973505 — intervention group
Intervention type: DRUG
Intervention: Aromatase Inhibitor(Femara or Arimidex)
Description: Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd
Study NCT05673746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: acupuncture administration
Study NCT05673746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment of physician choice, according to the standard of care
Description: treatment of physician choice, according to the standard of care for the treatment of chemotherapy-induced peripheral neuropathy, including neuropathic pain
Study NCT05673746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment of physician choice, according to the standard of care
Description: treatment of physician choice, according to the standard of care for the treatment of chemotherapy-induced peripheral neuropathy, including neuropathic pain
Study NCT00068458 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium-Rich Diet
Description: 1,200 - 2,500 mg/day. 6 month intervention
Study NCT00068458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2: Exercise + Calcium-Rich Diet
Description: Dietary counseling + material promoting strength training an aerobic activity + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
Study NCT00068458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise + Fruit & Vegetable, Low Fat + Calcium Diet
Description: 1,200 - 2,500 Calcium intake per day. 6 month intervention period.
Study NCT02776475 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sacral neuromodulation device turned off
Description: Each patient will be to have the sacral neuromodulation device turned off for four consecutive weeks.
Study NCT01485406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2830930A
Description: 1 dose administered intramuscularly
Study NCT01485406 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: 1 dose administered intramuscularly
Study NCT01695954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin 2 mg tablets taken at bedtime in Arm A and in the morning in Arm B.
Study NCT01695954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir 400 mg tablets x 2 taken daily in Arm B
Study NCT01695954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100 mg tablets taken daily in Arm B
Study NCT01695954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenz 600 mg tablets taken at bedtime in Arm A
Study NCT02614235 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pocket-ECG III system
Description: Continuous cardiac telemetry until diagnosis or a maximum of two months
Study NCT02614235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pocket-ECG III system
Description: Continuous cardiac telemetry until diagnosis or a maximum of two months
Study NCT01363492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replagal (agalsidase alfa)
Description: 0.2 mg/kg administered over 40 minutes every other week (EOW)
Study NCT02611518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be administered as a single oral 500 mg on Day 1 and Day 14.
Study NCT02745041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate
Description: Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM guided treatment algorithm \[FIBTEM ≤ A5 10mm\]~FIBTEM A5 0mm (Flat Line) = 6g FC FIBTEM A5 1 - 4mm = 5g FC FIBTEM A5 5 - 6mm = 4g FC FIBTEM A5 7 - 8mm = 3g FC FIBTEM A5 9 - 10mm = 2g FC
Study NCT02745041 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprecipitate
Description: Fibrinogen replacement using Cryoprecipitate as per ROTEM guided treatment algorithm \[FIBTEM A5 ≤ 10mm\]~FIBTEM A5 0mm (Flat Line) = 20 Units Cryo FIBTEM A5 1- 4mm = 16 Units Cryo FIBTEM A5 5 - 6mm = 14 Units Cryo FIBTEM A5 7 - 8mm = 10 Units Cryo FIBTEM A5 9 - 10mm = 8 Units Cryo
Study NCT05695404 — intervention group
Intervention type: PROCEDURE
Intervention: Segmentectomy
Description: Lung resection
Study NCT02315417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab
Study NCT02315417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02315417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab open-label
Study NCT00252317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril and Trandolapril
Description: Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
Study NCT00252317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Captopril and Trandolapril
Description: Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
Study NCT00252317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril Test Dose and Trandolapril
Description: Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
Study NCT00252317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Captopril Test Dose and Trandolapril
Description: Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
Study NCT03903913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1226
Description: The drug product S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) nebulized with a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8% or 12% CO2.
Study NCT00917137 — intervention group
Intervention type: PROCEDURE
Intervention: TBNA + transbronchial lung biopsy + bronchial washing